vs
Side-by-side financial comparison of Ingersoll Rand (IR) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Ingersoll Rand is the larger business by last-quarter revenue ($2.1B vs $1.2B, roughly 1.7× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 12.7%, a 4.3% gap on every dollar of revenue. On growth, Ingersoll Rand posted the faster year-over-year revenue change (10.1% vs 10.1%). Ingersoll Rand produced more free cash flow last quarter ($461.5M vs $345.8M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 11.9%).
Ingersoll Rand Inc. is an American multinational company that provides flow creation and industrial products. The company was formed in February 2020 through the spinoff of the industrial segment of Ingersoll-Rand plc and its merger with Gardner Denver. Its products are sold under more than 40 brands across all major global markets.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
IR vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $1.2B |
| Net Profit | $266.1M | $203.5M |
| Gross Margin | 42.6% | — |
| Operating Margin | 18.7% | 21.2% |
| Net Margin | 12.7% | 17.0% |
| Revenue YoY | 10.1% | 10.1% |
| Net Profit YoY | 15.8% | 6.5% |
| EPS (diluted) | $0.67 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | $1.2B | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.7B | $897.8M | ||
| Q4 24 | $1.9B | $1.1B | ||
| Q3 24 | $1.9B | $1.1B | ||
| Q2 24 | $1.8B | $1.0B | ||
| Q1 24 | $1.7B | $902.0M |
| Q4 25 | $266.1M | $203.5M | ||
| Q3 25 | $244.1M | $251.4M | ||
| Q2 25 | $-115.3M | $-718.5M | ||
| Q1 25 | $186.5M | $-92.5M | ||
| Q4 24 | $229.8M | $191.1M | ||
| Q3 24 | $221.6M | $215.1M | ||
| Q2 24 | $185.0M | $168.6M | ||
| Q1 24 | $202.2M | $-14.6M |
| Q4 25 | 42.6% | — | ||
| Q3 25 | 43.7% | — | ||
| Q2 25 | 43.7% | — | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | 42.9% | — | ||
| Q3 24 | 43.8% | — | ||
| Q2 24 | 43.9% | — | ||
| Q1 24 | 44.7% | — |
| Q4 25 | 18.7% | 21.2% | ||
| Q3 25 | 19.2% | 5.1% | ||
| Q2 25 | 4.0% | -65.6% | ||
| Q1 25 | 17.6% | -6.2% | ||
| Q4 24 | 20.0% | 17.5% | ||
| Q3 24 | 19.1% | 24.7% | ||
| Q2 24 | 15.1% | 19.5% | ||
| Q1 24 | 17.6% | 7.3% |
| Q4 25 | 12.7% | 17.0% | ||
| Q3 25 | 12.5% | 22.3% | ||
| Q2 25 | -6.1% | -68.7% | ||
| Q1 25 | 10.9% | -10.3% | ||
| Q4 24 | 12.1% | 17.6% | ||
| Q3 24 | 11.9% | 20.4% | ||
| Q2 24 | 10.2% | 16.5% | ||
| Q1 24 | 12.1% | -1.6% |
| Q4 25 | $0.67 | $3.34 | ||
| Q3 25 | $0.61 | $4.08 | ||
| Q2 25 | $-0.29 | $-11.74 | ||
| Q1 25 | $0.46 | $-1.52 | ||
| Q4 24 | $0.57 | $2.97 | ||
| Q3 24 | $0.54 | $3.42 | ||
| Q2 24 | $0.45 | $2.49 | ||
| Q1 24 | $0.50 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $1.4B |
| Total DebtLower is stronger | $4.8B | $5.4B |
| Stockholders' EquityBook value | $10.1B | $4.3B |
| Total Assets | $18.3B | $11.7B |
| Debt / EquityLower = less leverage | 0.47× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.5B | $2.4B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $1.1B | $1.4B | ||
| Q1 24 | $1.5B | $1.4B |
| Q4 25 | $4.8B | $5.4B | ||
| Q3 25 | $4.8B | $5.4B | ||
| Q2 25 | $4.8B | $5.4B | ||
| Q1 25 | $4.8B | $5.4B | ||
| Q4 24 | $4.8B | $6.1B | ||
| Q3 24 | $4.8B | $6.1B | ||
| Q2 24 | $4.8B | $5.7B | ||
| Q1 24 | $2.7B | $5.7B |
| Q4 25 | $10.1B | $4.3B | ||
| Q3 25 | $10.1B | $4.0B | ||
| Q2 25 | $10.1B | $3.7B | ||
| Q1 25 | $10.5B | $4.2B | ||
| Q4 24 | $10.2B | $4.1B | ||
| Q3 24 | $10.3B | $4.2B | ||
| Q2 24 | $10.0B | $3.8B | ||
| Q1 24 | $9.9B | $3.7B |
| Q4 25 | $18.3B | $11.7B | ||
| Q3 25 | $18.2B | $11.4B | ||
| Q2 25 | $18.1B | $10.9B | ||
| Q1 25 | $18.4B | $11.5B | ||
| Q4 24 | $18.0B | $12.0B | ||
| Q3 24 | $18.2B | $12.3B | ||
| Q2 24 | $17.8B | $11.4B | ||
| Q1 24 | $15.5B | $11.3B |
| Q4 25 | 0.47× | 1.24× | ||
| Q3 25 | 0.47× | 1.35× | ||
| Q2 25 | 0.47× | 1.45× | ||
| Q1 25 | 0.45× | 1.29× | ||
| Q4 24 | 0.47× | 1.49× | ||
| Q3 24 | 0.47× | 1.47× | ||
| Q2 24 | 0.48× | 1.52× | ||
| Q1 24 | 0.27× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $499.0M | $362.5M |
| Free Cash FlowOCF − Capex | $461.5M | $345.8M |
| FCF MarginFCF / Revenue | 22.1% | 28.9% |
| Capex IntensityCapex / Revenue | 1.8% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.88× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.0M | $362.5M | ||
| Q3 25 | $354.6M | $474.6M | ||
| Q2 25 | $245.7M | $88.9M | ||
| Q1 25 | $256.4M | $429.8M | ||
| Q4 24 | $526.2M | $398.6M | ||
| Q3 24 | $404.0M | $398.7M | ||
| Q2 24 | $304.9M | $331.4M | ||
| Q1 24 | $161.6M | $267.2M |
| Q4 25 | $461.5M | $345.8M | ||
| Q3 25 | $325.5M | $459.4M | ||
| Q2 25 | $210.4M | $75.9M | ||
| Q1 25 | $222.7M | $415.9M | ||
| Q4 24 | $490.9M | $385.3M | ||
| Q3 24 | $374.3M | $388.0M | ||
| Q2 24 | $283.1M | $324.3M | ||
| Q1 24 | $99.3M | $260.3M |
| Q4 25 | 22.1% | 28.9% | ||
| Q3 25 | 16.6% | 40.8% | ||
| Q2 25 | 11.1% | 7.3% | ||
| Q1 25 | 13.0% | 46.3% | ||
| Q4 24 | 25.9% | 35.4% | ||
| Q3 24 | 20.1% | 36.8% | ||
| Q2 24 | 15.7% | 31.7% | ||
| Q1 24 | 5.9% | 28.9% |
| Q4 25 | 1.8% | 1.4% | ||
| Q3 25 | 1.5% | 1.3% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 1.9% | 1.2% | ||
| Q3 24 | 1.6% | 1.0% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 3.7% | 0.8% |
| Q4 25 | 1.88× | 1.78× | ||
| Q3 25 | 1.45× | 1.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 2.29× | 2.09× | ||
| Q3 24 | 1.82× | 1.85× | ||
| Q2 24 | 1.65× | 1.97× | ||
| Q1 24 | 0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IR
| Transferred At Point In Time | $1.5B | 71% |
| Transferred Over Time | $193.0M | 9% |
| Precision And Science Technologies Segment | $183.1M | 9% |
| Acquisitions In2024 | $175.6M | 8% |
| Acquisitions In2025 | $70.8M | 3% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
